Several years of research, supported by our investors
LATTICE MEDICAL, created at the end of 2017, makes the most of several years of research by Lille University Hospital and the University of Lille in tissue engineering for the regeneration of autologous adipose tissue. The company operates a patented technology that has been extended internationally, with its first application in breast reconstruction.
Betting on the reconstructive surgery of tomorrow
LATTICE MEDICAL aims to revolutionise breast reconstruction with its MATTISSE implant, enabling autologous reconstruction for all patients and becoming the market leader in human soft tissue repair. Our ambition is to replace silicone implants and help 40,000 women by 2030 to have simpler, risk-free breast reconstruction.
Join the adventure
become an investor
The current global market for breast reconstruction is estimated at €1.2 billion in 2019, growing by 5% a year to reach €1.8 billion in 2027. In parallel, the market for cosmetic breast surgery is estimated at €1.7 billion in 2020. The three growth markets are the United States, the world’s largest market, Europe and Brazil, which together account for a market worth €900 million. LATTICE MEDICAL is targeting 5% of this market by 2030.
Receive our investor news newsletter
Receive our investor newsletter directly in your mailbox every month
You won't be the only one to place your trust in us.
Our partners have been with us for many years and we are proud to count them among our supporters.
Our financial partners:
Next steps in the
development of Lattice Medical
The roadmap has already been written for the coming years. Here's a glimpse of what we're planning for the future.
A year ago, we began clinical trials on our MATTISSE breast prosthesis.
Communication of our first clinical results on 10 patients with 6 to 12 months of follow-up, both on safety data and on the performance of the MATTISSE implant.
End of inclusion of the last patient and finalisation of our technical file with a view to CE marking
Passing of the audit with our notified body for the validation of our quality system for the design, development and manufacture of breast implants.
Launch of clinical investigation in the USA with a view to FDA approval.
Launch of the European pre-market clinical investigation for our product RODIN.
